Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
08:53a SHAW COMMUNICATIONS : Five new recipients of Shaw Media-Hot Docs Funds announced
08:52a CYNOSURE : to Host Investor Event to Introduce SculpSure™, the World's First Hyperthermic Aesthetic Laser Treatment for Non-Invasive Fat Reduction
08:52a CREST NICHOLSON : unveils new Blossom Hill Farm show home in Henham
08:52aDJAOL to Buy Millennial Media--Update
08:52a RESEARCH AND MARKETS : Cervical Cancer - Pipeline Review, H1 2015
08:51a WAL MART STORES : Why technology is the linchpin of the omni-channel strategy
08:51a DSW : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
08:51a EUROPE MUST WAIT AT LEAST FIVE YEARS FOR BANK CONSOLIDATION : CEOs
08:50a European Central Bank President Mario Draghi's Opening Statement
08:50a KITRON ASA : Agreement related to manufacturing of medical equipment
Latest news
Advertisement
Hot News 
FORBIDDEN TECHNOLOGIES : Reports Loss In Half As Deferred Revenue Rises
Earnings, Trading Statements Calendar - Week Ahead
Integra LifeSciences to Acquire Total Ankle Replacement (Salto Talaris(R)) and Silastic Toe Replacement (Futura(TM)) Product Portfolios From Tornier N.V.
EMPRESARIA : Expects Annual Results To Beat Current Market Expectations
DART : AGM Statement and Announcement of Aircraft Order 03 September 2015
Most Read News
09/02 AUSTRALIAN COMPETITION AND CONSUMER COMMISSION : ACCC concludes review of 'free range' and other similar claims in the pork industry
09/02 MRB MALAYSIAN RUBBER BOARD : Courtesy Visit By H.E Thai Ambassador to Malaysian Rubber Board
09/02 CEPA CANADIAN ENERGY PIPELINE ASSOCIATION : Do your beliefs about pipelines stand up to the science?
09/02 MRB MALAYSIAN RUBBER BOARD : Director General Attends Deputy Minister’s Hari Raya Aidil Fitri Celebration
09/02 HARRINGTON GLOBAL LIMITED : Acquires Securities of Range Energy Resources Inc.
Most recommended articles
08:52aDJAOL to Buy Millennial Media--Update
08:51a EUROPE MUST WAIT AT LEAST FIVE YEARS FOR BANK CONSOLIDATION : CEOs
08:50a ECB keeps QE total unchanged, promises more if necessary
08:47aDJCanada's Trade Deficit Narrowed in July
08:46aDJU.S. Jobless Claims Up By 12,000